Madrigal Pharmaceuticals, Inc.
MDGL
Peringkat dalam Saham
#2013
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Harga Saham
$446.50
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$10.32B
Perubahan (1 hari)
-0.72%
Perubahan (1 tahun)
1.48%
Negara
US
Perdagangan Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Riwayat pemecahan saham untuk Madrigal Pharmaceuticals, Inc. (MDGL)
Saham Madrigal Pharmaceuticals, Inc. (simbol: MDGL) telah mengalami total 1 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Jul 25, 2016.
Satu lembar saham MDGL yang dibeli sebelum Jul 25, 2016 sekarang setara dengan 0.028571428571429 lembar saham MDGL.
Pemecahan saham terbaru terjadi pada Jul 25, 2016.
Satu lembar saham MDGL yang dibeli sebelum Jul 25, 2016 sekarang setara dengan 0.028571428571429 lembar saham MDGL.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| 2016-07-25 | 1:35 | x0.028571428571429 | x0.028571428571429 |
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
